Phase 2b study to evaluate the rate of onset of action of RDX227675 along with safety and efficacy in patients with chronic kidney disease (CKD) with or without heart failure (HF)
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs RDX 7675 (Primary)
- Indications Hyperkalaemia; Kidney disorders
- Focus Therapeutic Use
- 21 Nov 2017 According to a company media release, Ardelyx has made the decision to discontinue development of RDX7675, including both the onset-of-action and Phase 3 studies because of an unexpected and drug-related reduction in serum bicarbonate observed in the onset-of-action trial.
- 21 Nov 2017 Status changed from recruiting to discontinued according to an Ardelyx media release.
- 07 Nov 2017 According to an Ardelyx media release, the company anticipates providing an update from the study by the end of 2017.